Mytos Launches Automated CDMO for Stem Cell Therapies
Mytos, a pioneering biotech company, has launched its automated contract development and manufacturing organization (CDMO) for stem cell-derived therapies at the Cell and Gene Therapy Catapult's (CGT Catapult) Stevenage Manufacturing Innovation Centre. The facility targets clinical readiness by September 2026, with an annual capacity of up to 1,500 autologous or 25,000 allogeneic doses.
Mytos' CEO, Ali Afshar, PhD, believes that manual manufacturing constraints have hindered the scalability of regenerative medicines. To address this, Mytos has developed the iDEMTM automation technology, which powers its new CDMO. This technology aims to reduce costs and accelerate the scaling of regenerative medicines.
The new facility, a collaboration between Mytos and CGT Catapult, is designed to de-risk the transition to a CDMO and support innovation in manufacturing technology. CGT Catapult's expertise and track record in the field made the Stevenage Manufacturing Innovation Centre an ideal launch site for Mytos. Matthew Durdy, CEO of CGT Catapult, expressed support for Mytos' automated technology and its potential to accelerate advanced therapies.
Upon completion in September 2026, the facility is expected to produce up to 1,500 autologous doses or 25,000 allogeneic doses annually. This significant capacity increase, enabled by Mytos' automation technology, is set to revolutionise the manufacturing of regenerative medicines, making them more accessible and affordable.
Read also:
- Comprehensive Cancer Care Strategy Encompassed by Siemens Healthineers Entirely
- Fiercely battling for survival, a student hails from Ludwigsburg
- Mystery Disease Kills Thousands of Birds in Kazakhstan, Leaving Farmers in Limbo
- Recipients of 2024 ERC Starting Grants from the National Centre for Scientific Research (CNRS)